ELPIS Human umbilical cord mesenchymal stem cells(Huaxiayuan Cell Engineering)

ELPIS人脐带间充质干细胞（华夏源细胞工程)

Report date: 2026/02/11 20:01:36

Base Information

Drug NameELPIS Human umbilical cord mesenchymal stem cells(Huaxiayuan Cell Engineering)
Drug Alias NameELPIS人脐带间充质干细胞注射液
ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Mesenchymal stem cells therapy
Mechanisms of ActionStem cell replacements
TargetsNot applicable
Therapy Area/IndicationsPlaque psoriasisLupus NephritisAcute-On-Chronic Liver Failure +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesHuaxiayuan Cell Engineering Group Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesJiangxi Huaxiayuan Biotechnology Co LtdHuaxiayuan (Shanghai) Biotechnology Co LtdHuaxiayuan Cell Engineering Group Co Ltd
Inactive CompaniesN/A
Active IndicationsPlaque psoriasisLupus NephritisAcute-On-Chronic Liver Failure +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A